R. Laverty
About
R. Laverty is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology.
According to data from OpenAlex, R. Laverty has authored 89 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Cellular and Molecular Neuroscience, 22 papers in Molecular Biology and 18 papers in Physiology. Recurrent topics in R. Laverty's work include Neuroscience and Neuropharmacology Research (23 papers), Neurotransmitter Receptor Influence on Behavior (18 papers) and Nitric Oxide and Endothelin Effects (11 papers). R. Laverty is often cited by papers focused on Neuroscience and Neuropharmacology Research (23 papers), Neurotransmitter Receptor Influence on Behavior (18 papers) and Nitric Oxide and Endothelin Effects (11 papers). R. Laverty collaborates with scholars based in New Zealand, Slovakia and United Kingdom. R. Laverty's co-authors include Kenneth M. Taylor, D.F. Sharman, Graham V. Goddard, Michael Dragunow, E. L. Phelan, Richard L. M. Faull, David W. J. Clark, Janet M. Ledingham, B A Callingham and Barbara Logan and has published in prestigious journals such as The Lancet, Circulation Research and The Journal of Physiology.
In The Last Decade
R. Laverty
89 papers receiving 3.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| R. Laverty New Zealand | 28 | 2.1k | 1.1k | 708 | 328 | 325 | 89 | 3.7k | ||
| I J Kopin United States | 34 | 2.1k 1.0× | 1.1k 1.0× | 667 0.9× | 216 0.7× | 383 1.2× | 70 | 4.2k | ||
| Ewan J. Mylecharane Australia | 18 | 2.5k 1.2× | 2.0k 1.8× | 866 1.2× | 503 1.5× | 277 0.9× | 39 | 4.2k | ||
| Marthe Vogt Slovakia | 31 | 1.9k 0.9× | 1.2k 1.1× | 984 1.4× | 254 0.8× | 273 0.8× | 91 | 4.2k | ||
| E. Costa United States | 24 | 2.0k 1.0× | 1.1k 1.0× | 525 0.7× | 168 0.5× | 302 0.9× | 46 | 3.1k | ||
| L. Charles Murrin United States | 35 | 2.6k 1.3× | 2.1k 1.9× | 505 0.7× | 251 0.8× | 392 1.2× | 80 | 4.1k | ||
| Robert J. Naylor United Kingdom | 39 | 2.9k 1.4× | 2.0k 1.8× | 571 0.8× | 466 1.4× | 488 1.5× | 134 | 4.9k | ||
| P. Slater United Kingdom | 30 | 2.2k 1.0× | 1.2k 1.1× | 521 0.7× | 412 1.3× | 499 1.5× | 134 | 3.1k | ||
| N.‐E. Andén Sweden | 26 | 2.7k 1.3× | 1.3k 1.2× | 792 1.1× | 266 0.8× | 560 1.7× | 46 | 4.3k | ||
| S Z Langer France | 25 | 2.0k 1.0× | 2.0k 1.8× | 798 1.1× | 221 0.7× | 156 0.5× | 48 | 3.5k | ||
| D.F. Sharman Slovakia | 30 | 1.6k 0.8× | 1.0k 0.9× | 510 0.7× | 305 0.9× | 170 0.5× | 94 | 3.5k |
Countries citing papers authored by R. Laverty
Since
Specialization
Citations
This map shows the geographic impact of R. Laverty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Laverty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Laverty more than expected).
Fields of papers citing papers by R. Laverty
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by R. Laverty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Laverty. The network helps show where R. Laverty may publish in the future.
Co-authorship network of co-authors of R. Laverty
This figure shows the co-authorship network connecting the top 25 collaborators of R. Laverty. A scholar is included among the top collaborators of R. Laverty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Laverty. R. Laverty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Laverty, R.. (2024). The Shift from Phenomenological to Physics-Based Modeling of Polymers: 2024 Benjamin Franklin Medal in Mechanical Engineering presented to Mary C. Boyce, Ph.D.. Journal of the Franklin Institute. 361(18). 107375–107375.
2.
Ledingham, Janet M. & R. Laverty. (2005). Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Clinical and Experimental Pharmacology and Physiology. 32(1-2). 76–85.
3.
Ledingham, Janet M. & R. Laverty. (2002). Fluvastatin remodels resistance arteries in genetically hypertensive rats, even in the absence of any effect on blood pressure. Clinical and Experimental Pharmacology and Physiology. 29(10). 931–934.
4.
Liu, Hanzhong, Janet M. Ledingham, Ian Mullaney, & R. Laverty. (2002). Endothelial Function In Mesenteric Resistance Arteries From The Genetically Hypertensive Rat. Clinical and Experimental Pharmacology and Physiology. 29(5-6). 405–411.
5.
Ledingham, Janet M. & R. Laverty. (2001). Effects Of Nitric Oxide Synthase Inhibition And Low‐Salt Diet On Blood Pressure And Mesenteric Resistance Artery Remodelling In Genetically Hypertensive Rats. Clinical and Experimental Pharmacology and Physiology. 28(9). 761–763.
6.
Sansom, Andrew J., Paul F. Smith, Cynthia L. Darlington, & R. Laverty. (2000). The effects of protein kinase C and calmodulin kinase II inhibitors on vestibular compensation in the guinea pig. Brain Research. 882(1-2). 45–54.
7.
Ledingham, Janet M., et al.. (2000). Effects Of Chronic Inhibition Of Nitric Oxide Synthase In The Genetically Hypertensive Rat. Clinical and Experimental Pharmacology and Physiology. 27(8). 647–649.
8.
Laverty, R., et al.. (2000). Basilar Artery Remodelling In The Genetically Hypertensive Rat: Effects Of Nitric Oxide Synthase Inhibition And Treatment With Valsartan And Enalapril. Clinical and Experimental Pharmacology and Physiology. 27(8). 642–646.
9.
Ledingham, Janet M., et al.. (2000). Prevention of Increases in Blood Pressure and Left Ventricular Mass and Remodeling of Resistance Arteries in Young New Zealand Genetically Hypertensive Rats: The Effects of Chronic Treatment with Valsartan, Enalapril and Felodipine. Journal of Vascular Research. 37(2). 134–145.
10.
Ledingham, Janet M. & R. Laverty. (1998). Renal afferent arteriolar structure in the genetically hypertensive (GH) rat and the ability of losartan and enalapril to cause structural remodelling. Journal of Hypertension. 16(Supplement). 1945–1952.
11.
Zheng, Yiwen & R. Laverty. (1998). Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Brain Research. 795(1-2). 257–263.
12.
Sansom, Andrew J., Vicki A. Brent, Paula E. Jarvie, et al.. (1997). In vitro phosphorylation of medial vestibular nucleus and prepositus hypoglossi proteins during behavioural recovery from unilateral vestibular deafferentation in the guinea pig. Brain Research. 778(1). 166–177.
13.
Ledingham, Janet M. & R. Laverty. (1996). REMODELLING OF RESISTANCE ARTERIES IN GENETICALLY HYPERTENSIVE RATS BY TREATMENT WITH VALSARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST. Clinical and Experimental Pharmacology and Physiology. 23(6-7). 576–578.
14.
Ledingham, Janet M., et al.. (1995). EFFECT OF FELODIPINE TREATMENT AND WITHDRAWAL ON BLOOD PRESSURE AND CARDIOVASCULAR STRUCTURE IN NEW ZEALAND GENETICALLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology. 22(s1). S326–8.
15.
Ledingham, Janet M., et al.. (1994). REMODELLING OF RESISTANCE ARTERIES BY TREATMENT WITH ENALAPRIL IN THE NEW ZEALAND GENETICALLY HYPERTENSIVE RAT. Clinical and Experimental Pharmacology and Physiology. 21(3). 235–237.
16.
Bilkey, David K., et al.. (1992). The infusion of an NMDA antagonist into perirhinal cortex suppresses amygdala-kindled seizures. Brain Research. 587(2). 285–290.
17.
McNaughton, Neil, et al.. (1990). Effects of ethanol and Ro 15-4513 in an electrophysiological model of anxiolytic action. Neuroscience. 35(3). 669–674.
18.
Bilkey, David K., et al.. (1990). TheN-methyl-D-aspartate antagonists aminophosphonovalerate and car☐ypiperazinephosphonate retard the development and expression of kindled seizures. Brain Research. 506(2). 227–235.
19.
Laverty, R., et al.. (1989). Dose-dependent reduction by Ro 15-4513 in mice of the effects of ethanol and some other general depressant drugs. European Journal of Pharmacology. 162(2). 265–271.
20.
Taylor, Kenneth M. & R. Laverty. (1969). THE METABOLISM OF TRITIATED DOPAMINE IN REGIONS OF THE RAT BRAIN IN VIVO—II. Journal of Neurochemistry. 16(9). 1367–1376.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by I J Kopin Breakdown of academic impact, for papers by Ewan J. Mylecharane Breakdown of academic impact, for papers by Marthe Vogt Breakdown of academic impact, for papers by E. Costa Breakdown of academic impact, for papers by L. Charles Murrin Breakdown of academic impact, for papers by Robert J. Naylor Breakdown of academic impact, for papers by P. Slater Breakdown of academic impact, for papers by N.‐E. Andén Breakdown of academic impact, for papers by S Z Langer Breakdown of academic impact, for papers by D.F. Sharman